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ABSTRACT
Antimicrobial resistance is a global problem and is
being addressed through national strategies to improve
diagnostics, develop new antimicrobials and promote
antimicrobial stewardship. A narrative review of the
literature was undertaken to ascertain the value of C
reactive protein (CRP) and procalcitonin,
measurements to guide antibacterial prescribing in
adult patients presenting to GP practices with
symptoms of respiratory tract infection (RTI). Studies
that were included were randomised controlled trials,
controlled before and after studies, cohort studies and
economic evaluations. Many studies demonstrated that
the use of CRP tests in patients presenting with RTI
symptoms reduces antibiotic prescribing by 23.3% to
36.16%. Procalcitonin is not currently available as a
point-of-care testing (POCT), but has shown value for
patients with RTI admitted to hospital. GPs and
patients report a good acceptability for a CRP POCT
and economic evaluations show cost-effectiveness of
CRP POCT over existing RTI management in primary
care. POCTs increase diagnostic precision for GPs in
the better management of patients with RTI. CRP
POCT can better target antibacterial prescribing by GPs
and contribute to national antimicrobial resistance
strategies. Health services need to develop ways to
ensure funding is transferred in order for POCT to be
implemented.
BACKGROUND
Antimicrobial resistance (AMR) is a global
healthcare and economic problem, and
should be a priority for all the World’s gov-
ernments.1 The Director General of the
WHO, Margaret Chan, has stated with
respect to AMR that—‘No action today
means no cure tomorrow’.2 The UK Chief
Medical Ofﬁcer has, likewise, repeatedly
emphasised the threat of AMR3 and the
recently published UK Strategy for AMR has
three aims: 1 improving knowledge and
understanding of AMR; 2 conserving and
stewarding the effectiveness of existing treat-
ments; and3 stimulating the development of
new antibiotics, diagnostics and novel therap-
ies.4 Substantial new or redeployed funding
will be needed in order to deliver this strat-
egy, as the amount spent on research in this
area is relatively small.5 The UK public has
recognised the importance of AMR by voting
for the challenge of the Longitude Prize
2014 to be to create “a cheap, accurate, rapid
and easy-to-use point-of-care diagnostic test
for bacterial infections”.6 The aim is to ﬁnd
the test that will have the greatest impact glo-
bally on antibiotic resistance and the prize
will be open until 2019. http://www.
longitudeprize.org/challenge/antibiotics.
Community prescribing of antibacterial
medication varies considerably across
European countries and in general practice
there are individual community and country-
level associations in the prescribing of anti-
bacterials—the prevalence of resistance
underscoring the need to avoid unnecessary
prescription many of which are for respira-
tory tract infections (RTIs) in the commu-
nity.7 RTIs are the most frequent infections
encountered in primary care and most
people presenting to a GP with an acute
uncomplicated RTI still receive an antibiotic
prescription, with many doctors and patients
believing that this is the ‘right thing’ to do.8
This is despite the facts (1) that most RTIs
are viral, (2) that there is only limited evi-
dence to support the use of antibiotics in
acute bronchitis, sore throat, sinusitis and
otitis media9–12 and (3) the evidence from
systematic reviews and other studies suggests
little, if any, beneﬁt is achieved from the pre-
scription of antibiotics, except in elderly
patients at high risk of pneumonia.9 13–15
A recent study of GP prescribing in England
found that the likelihood of GPs prescribing
antibiotics for coughs and colds increased by
40% between 1999 and 2011, despite
Government recommendations to reduce
prescribing for illnesses largely caused by
viruses.16 Clarity of diagnosis was questioned
in a cross-sectional study, which showed there
were considerable differences in GPs’
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diagnosis of pneumonia between Denmark and Spain;17
moreover, there is evidence from diagnostic studies to
show the poor accuracy of clinical diagnosis of pneumo-
nia in general practice (with radiographic proof as refer-
ence standard).18–20
So, how can the prescribing of antibiotics for RTIs in
primary care be made more appropriate? How might
improvements in diagnostic testing promote this?
POINT-OF-CARE TESTS
Potentially, primary care prescribers can use
point-of-care testing (POCTs) to inform their manage-
ment of disease, especially if these tests can be per-
formed within the duration of a patient visit, with results
obtained within 5 min of taking the sample. If sufﬁ-
ciently sensitive and speciﬁc, these tests can offer object-
ive precision to clinical assessment of the patient’s signs
and symptoms.
A recent survey of Dutch GPs reported the most
common point-of-care tests currently used by family phy-
sicians were: blood glucose (96%), urine leucocytes or
nitrite (96%), urine pregnancy (94%), haemoglobin
(58%), and CRP (48%). The most commonly desired
point-of-care tests were: D-dimer (70%), troponin
(65%), brain natriuretic peptide (BNP; 62%), chlamydia
(60%) and International Normalised Ratio (INR; 54%).
Family practitioners expected point-of-care tests to have
a positive effect on patient satisfaction (93%), diagnostic
certainty (89%), antibiotics use (84%) and substitution
to primary care (78%). They considered the proven
effect on clinical management (46%), and the tests’ reli-
ability (35%) to be important aspects of point-of-care
tests. Respondents wanted point-of-care tests to help
them diagnose acute conditions, such as acute thrombo-
embolic disorders (D-dimers), cardiac disorders (tropo-
nin, BNP) and infections (CRP, chlamydia).21
However, are there any useful POCTs to help predict
RTI in general practice and to reduce unnecessary anti-
biotic prescribing, as advocated in the UK AMR Strategy?
NARRATIVE REVIEW
Aim
To consider whether POCTs improve antibacterial pre-
scribing, whether they are acceptable for patients and
GPs, and their cost-effectiveness for the National Health
Service (NHS).
Design and setting
Narrative review of the literature on POCT and antibac-
terial use in RTI in a primary care setting.
Method
A literature search was undertaken to review the litera-
ture on biomarker Point-of-Care Tests (POCT) for adults
presenting to GPs with symptoms of RTI in order to:
▸ Determine whether POCTs can reduce antibacterial
prescribing;
▸ Ascertain the safety and acceptability of POCTs for
patients and GPs;
▸ Determine the cost-effectiveness of POCTs in an NHS
setting;
Papers reviewed were in English, and published
between 1995 and 2015.
Search terms were: CRP, C-reactive protein, biomarkers,
procalcitonin, infections, antibiotics, antimicrobials, primary
care, point of care testing, infection respiratory tract.
Databases searched were: EMBASE, Excerpta Medica
(Ovid), Journals@Ovid Full Text (Ovid), PubMed,
MEDLINE (Ovid).
Highwire Press, nature.com, ScienceDirect—All
Content—V.4 (Elsevier), SpringerLink, Wiley Interscience
Journals, NHS Evidence, The Cochrane Collaboration.
RESULTS
The ﬁrst search yielded 1022 references. This was
further reﬁned down to 76 references by focusing on sys-
tematic reviews, clinical trials and economic analyses in
human adults, and in RTIs presenting in primary care.
Excluded studies included laboratory studies, studies in
children, duplications and non-systematic reviews.
The pivotal studies of randomised controlled trials,
cluster randomised controlled trials, economic evalua-
tions and systematic reviews are shown in table 1.
Measurement of C reactive protein (CRP) and procal-
citonin biomarkers have been advocated as additional
tests to assist proper clinical examination, especially (1)
where there is a high degree of diagnostic uncertainty,
(2) for patients who are very worried and/or demanding
an antibiotic, and (3) to differentiate the seriously ill
from the non-seriously ill. Procalcitonin has greater sen-
sitivity and speciﬁcity for distinguishing bacterial and
viral infection in hospital settings, and multiple analyses
point to its value in guiding hospital antibiotic use for
patients with pneumonia, leading to reductions in anti-
biotic use without harm to patients.22 23 However,
studies show that procalcitonin does not yet add sufﬁ-
cient value for decision-making in primary care,24–26
whereas CRP POCT appears better in correctly predict-
ing the absence of radiographic pneumonia.24
Moreover, procalcitonin has not yet proven to be suit-
able for deployment as a POCT in general practice,
having a turnaround time (depending on the system) of
18–30 min; CRP POCTs, by contrast, have a turnaround
of <5 min, thus giving a result within the ambit of a
standard NHS GP consultation.
CRP Background
CRP is a major acute-phase plasma protein which is pro-
duced in response to infection or tissue injury. It has
Ca2+-dependent binding speciﬁcity for phosphocholine
(PCh), a constituent of many bacterial and fungal poly-
saccharides, and of most biological cell membranes. The
main biological function of CRP is determined by this
ability to recognise pathogens and damaged host cells,
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and to mediate their elimination by recruiting the com-
plement system along with phagocytic cells. PCh, the
principal CRP ligand, is widely distributed in the tei-
choic acids, capsular carbohydrates, and lipopolysacchar-
ides of bacteria and other microorganisms.27 CRP was
discovered and named because of its reactivity with the
PCh residues of Cpolysaccharide (PnC), the teichoic
acid of Streptococcus pneumoniae.28 CRP is synthesised by
the liver in response to factors released by macrophages
and fat cells (adipocytes). Like many acute phase pro-
teins, CRP is normally present at trace levels in serum,
but increases rapidly and dramatically in response to a
variety of infectious or inﬂammatory stimuli.29 Its levels
typically are highest in patients with a bacterial infection
and are lower in those with viral infection. Rapid tests
for CRP were introduced into general practice about
20 years ago and are widely used as a diagnostic in the
Netherlands and Nordic countries, mostly for RTI.30
CRP evidence
A recent Cochrane review concluded that a point-of-care
biomarker (eg, CRP) to guide antibiotic treatment of
acute respiratory infections (ARIs) in primary care can
signiﬁcantly reduce antibiotic use, ﬁgure 1.31 Studies
included in the ﬁnal analysis included randomised and
cluster randomised controlled trials in England, Wales,
the Netherlands, Poland, Spain, Belgium, Denmark and
Russia to demonstrate that using CRP POCT in primary
care can signiﬁcantly reduce the initial prescribing rate
of antibiotics. Reported reductions were 36.16% (37.6%
vs 58.9%) in patients presenting with acute cough/lower
respiratory tract infection, LRTI (including acute bron-
chitis, pneumonia and infectious exacerbations of
chronic obstructive pulmonary disease (COPD) or
asthma),30 31.25% (33% vs 48%) in upper and lower
RTI,14 24.4% (59% vs 78%) in sinusitis,32 23.3% (43.4%
vs 56.6%) in LRTI or rhinosinusitis33 and 6.5% (43% vs
46%) in respiratory infections.34 In an uncontrolled
observational study, Swiss GPs who used CRP as part of
a clinical assessment of patients presenting with acute
cough were observed to prescribe antibiotics in 22% of
consultations which is considerably lower than studies
from other countries.35 These studies, together with sys-
tematic reviews, offer guidance on the value of measured
levels of CRP as both positive and negative prognostic
indicators of whether to administer antibiotics or not.36 37
Interpretive and prescribing criteria, have been devel-
oped from a consensus of collaborators in two consortia:
the ‘Improving Management of Patients with Acute
cough by C-Reactive Protein Point of Care Testing and
Communication Training (IMPAC3T) Programme’ and
the Genomics to Combat Resistance against Antibiotics in
Community-acquired LRTI in Europe (GRACE) consor-
tium.14 38 These groups propose:
▸ CRP levels <20 mg/L—Self-limiting LRTI. Withhold
antibiotics
▸ CRP 21–50 mg/L—Most patients have self-limiting
LRTI. Assessment of signs, symptoms, risk factors
and CRP is important. Withhold antibiotics in most
cases.
▸ CRP 51–99 mg/L—Assessment of signs, symptoms,
risk factors and CRP is crucial. Withhold antibiotics
in the majority of cases and consider delayed antibio-
tics in the minority of cases.
▸ CRP >100 mg/L.—Severe infection. Prescribe
antibiotics14
Similar criteria have been proposed by other groups,
including the UK National Institute for Health and Care
Excellence (NICE). These are given below and com-
pared in table 2.
Figure 1 Forest plots for randomised and cluster randomised controlled trials from Cochrane review Biomarkers as point-of-care
tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care.31
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Both general practitioners (GPs) and patients appear
to ﬁnd using the test acceptable, with one Dutch study
showing CRP POCT to have little effect on GP workload
in 50% of practices.39 Patients were satisﬁed to be pro-
vided with the results of a reassuringly low CRP POCT
rather than receiving an antibiotic prescription.39–41
CRP testing has a role as an adjunct in effective commu-
nication with patients; clinicians and patients all rec-
ommend seeing the CRP in conjunction with the
overall assessment and caution against over reliance
on CRP results in isolation of clinical assessment.42 43
In elderly patients with bacterial infections, CRP
POCT reportedly had a sensitivity of diagnosing bac-
terial infection of 80.7% and a speciﬁcity of 96%, with
a positive predictive value 91.9% and negative predict-
ive value 89.8%.44
While most of these results are promising, a few
studies have sounded a note of caution, particularly on
the ability of CRP to distinguish between bacterial and
viral infection. One Dutch study of LRTIs found that a
CRP >20 mg/L (OR 2.1–4.6), along with an erythrocyte
sedimentation rate >50 (OR 2.3–3.3), were independent
Table 2 Criteria for management of RTIs in general practice with CRP POCT after proper clinical examination of the patient
Management
Draft NICE guidance
for Pneumonia49
Dutch GP
practice
guideline54
GRACE
study14 ERS51
Self-limiting RTI.
Do not routinely offer antibiotic therapy.
Pneumonia unlikely.
Give education
CRP less than 20 mg/L CRP less than
20 mg/L
CRP less than
20 mg/L
CRP less than
20 mg/L
Majority of patients have self-limiting LRTI.
Assessment of signs, symptoms, risk
factors and CRP is important.
Withhold antibiotics, in most cases
CRP 21–
50 mg/L
Assessment of signs, symptoms, risk
factors and CRP is crucial.
Withhold antibiotics in the majority of cases
and consider delayed antibiotics in the
minority of cases
CRP 51–
99 mg/L
Consider a delayed antibiotic prescription.
Clinical presentation decisive.
Prescribe antibiotics only in patients with a
high risk of complications*
CRP between
20 and 100 mg/L
CRP between
20 and 100 mg/L
Severe infection.
High risk of pneumonia.
Offer antibiotic therapy
CRP greater than
100 mg/L
CRP greater than
100 mg/L
CRP greater
than 100 mg/L
CRP greater
than 100 mg/L
*Complicated respiratory tract infection.
A complicated respiratory tract infection is an infection with an increased risk of a complicated course (mortality or hospital admission). Two
groups are distinguished.
1. Patients with a probable diagnosis of pneumonia based on:
▸ Acute cough AND:
– Being severely ill, with for example, tachypnoea, tachycardia, hypotension (systolic blood pressure <90, diastolic blood
pressure <60 mm Hg) or confusion;
– Being moderately ill and unilateral auscultatory abnormalities (however, the absence of auscultatory abnormalities
does not rule out pneumonia);
– An infiltrate on chest X-ray;
– A course >7 days with fever and cough (without abnormalities on physical examination).
– For values between 20 and 100 mg/L, the clinical presentation determines policy, along with risk factors such as heart
failure, diabetes mellitus, COPD, asthma, age <3 months or >75 years;
2. Patients with another risk factor for a complicated course.
▸ Other risk factors—particularly age and comorbidities—should also be included in the evaluation of patients with acute
cough. The following factors increase risk of hospital admission and mortality:
– Age <3 months or >75 years;
– In children, cardiovascular and pulmonary conditions (except asthma);
– In adults: heart failure, severe COPD, diabetes mellitus (esp. with use of insulin), neurological conditions, severe renal
insufficiency;
– A disrupted immune system (owing to oncological conditions, renal insufficiency).54
CRP, C reactive protein; COPD, chronic obstructive pulmonary disease; POCT, point-of care-test; RTI, respiratory tract
infection; NICE, National Institute for Health and Care Excellence.
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predictors for viral or bacterial LRTI, but could not
delineate between these two aetiologies.45
Is withholding antibiotics based on CRP POCT safe?
In a Russian study of patients with acute cough/LRTI
(including acute bronchitis, pneumonia and infectious
exacerbations of COPD or asthma), participants were
randomised by GPs to normal care or to care informed
by a CRP POCT. As well as a signiﬁcant reduction in
antibiotic prescribing, the referral rate for chest radiog-
raphy was signiﬁcantly lower in the intervention group
(55.4%) as compared to the control group (76%;
p=0.004).30 Another Dutch study showed that GPs’ use
of CRP POCT signiﬁcantly reduced antibiotic prescrib-
ing for LRTIs, without compromising patients’ recovery
and satisfaction with care.40 This study also enhanced
general consultation skills and showed that proper dis-
cussion of the test results with the patient offered an
important contribution to better antibiotic stewardship.
While near patient tests can add diagnostic precision
to a standard clinical examination, these are not 100%
reliable.24 Any strategy reducing antibiotic use may have
rare adverse consequences due to untreated infection.
Use of the test is not a substitute for a proper clinical
examination and ‘safety net’ advice for those not reco-
vering as expected.
Economic evaluations of CRP POCTs
In an observational study of the presentation, manage-
ment, and outcomes of patients with acute cough and
LRTI in primary care settings in the Netherlands, the
total mean cost per patient in the ‘usual care’ group was
€35.96, with antibiotics prescribed to 68% of patients;
€37.58 per patient managed by GPs using CRP POCT
(antibiotic prescribing, 39%); €25.61 per patient
managed by GPs trained in enhanced communication
skills (antibiotic prescribing 33%); and €37.78 per
inpatient managed by GPs using both interventions
(antibiotic prescribing, 23%). It is less clear how such
outcomes translate between national healthcare systems
varying in consultation format, and in the choice and
cost of the particular antibiotics prescribed.46 In a
primary care study undertaken in Norway and Sweden,
CRP POCT testing was associated with non-signiﬁcant
reductions in antibiotic prescribing (p=0.078) and
increased cost (p=0.092). Despite this, CRP POCT was
also associated with a cost per quality-adjusted life year
(QALY) gain of £9391. At a Willingness-to-Pay threshold
of £30 000 per QALY gained, there is a 70% probability
of CRP POCT being cost-effective.47
Finally, in a modelling study undertaken in England,
3 models of CRP POCT use for patients presenting with
RTI symptoms were subjected to Markov analysis: GP
plus CRP, Practice nurse plus CRP POCT and GP plus
CRP POCT and communication training. All these
models were found to be more cost-effective than not
using any CRP POCT.48
Limitations of study
These include, the heterogeneity of presenting condi-
tions of patients for both upper and lower RTIs in the
studies evaluated and the different healthcare systems
that provide primary care services in different countries.
However, these limitations are somewhat ameliorated by
the designs of the studies selected—randomised con-
trolled and cluster randomised controlled trials.
Clinical guidelines for use of CRP in RTI
investigation for GPs
National Institute of Health and Care Excellence
Current draft clinical guidelines for pneumonia from the
NICE propose a number of actions to help GPs to
manage patients who present with symptoms of RTI.49
These include:
Consider a point-of-care C-reactive protein test for
patients presenting with lower respiratory tract infection
in primary care if it is not clear after clinical assessment
whether antibiotics should be prescribed. Use the results
of the C-reactive protein test to guide antibiotic prescrib-
ing as follows:
Do not routinely offer antibiotic therapy if the C-reactive
protein concentration is less than 20 mg/L.
Consider a delayed antibiotic prescription (a prescription
for use at a later date if symptoms worsen) if the
C-reactive protein concentration is between 20 mg/L and
100 mg/L.
Offer antibiotic therapy if the C-reactive protein concen-
tration is greater than 100 mg/L.
These NICE guidelines were developed following a sys-
tematic review and meta-analysis of the clinical and cost-
effective published evidence from randomised con-
trolled trials. The stratiﬁcation differs from the advice of
the IMPAC3T and GRACE consortia (above) only in not
subdividing the patients with CRP concentrations
between 20 and 100 mg/L.
Public Health England
Current guidance from Public Health England offers
strategies for the management of acute upper and lower
RTIs in general practice, including community-acquired
pneumonia.50 This guidance is expected to be updated
in line with the NICE guidance, given above, including
the use of CRP as a biomarker.
European guidance
The European Respiratory Society has produced
Guidelines for the management of adult lower RTI which
include the recommendation:
In patients with a suspected pneumonia, a test for serum-
level of C-reactive protein (CRP) can be done. A CRP
level of <20 mg/L at presentation, with symptoms for
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>24 h, makes the presence of pneumonia highly unlikely,
a level of >100 mg/L makes pneumonia likely.51
Table 2 compares the CRP-guided management of RTI
based on the various slightly differing sets of guideline
criteria outlined above.
Which countries use CRP POCT as a prognostic tool in
general practice?
Countries that use CRP POCT widely include: Denmark,
Norway, Sweden, Germany, the Netherlands, Switzerland
and Finland; countries that use CRP POCT to some
extent include: Estonia, Slovenia, Latvia, Czech
Republic, Hungary and Austria.52 Interestingly, most of
these countries have lower systemic antibacterial con-
sumption in the community than does the UK.53 The
Netherlands has particularly addressed antimicrobial
stewardship in primary care, and has one of the lowest
ambulatory antibiotic prescribing rates for humans in
Europe53 (ﬁgure 2). Its national guidelines (NHG
Guidelines)54 resemble those of GRACE and IMPACT,
and the draft NICE guidance, summarised in table 2.
Making comparisons between countries is not com-
plete without considering how different countries pay
for POCTs. In the UK, GPs would have to meet the add-
itional costs of CRP POCT in order to encourage uptake
of this technology; the alternative funding mechanisms
would need to be identiﬁed, for instance, by using
‘enhanced service’ contracting arrangements.
CONCLUSION
There is considerable and accumulating evidence that
measurements of CRP and procalcitonin are both
Figure 2 Consumption of antibacterials for systemic use (ATC group J01) at anatomical therapeutic chemical (ATC) group level
3 in the community, European Union/European Economic Area countries, 2012, expressed as defined daily dose (DDD) per
1000 inhabitants and per day. From European Centre for Disease Prevention and Control.53
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clinically valuable and cost-effective diagnostics.
Procalcitonin is not currently available as a POCT but
has shown value in patients admitted to hospital with
RTI. CRP POCT offers GPs a simple test that can be per-
formed within 5 min and this helps to distinguish
whether community patients with RTI need antibiotics
or not. The test is acceptable to both patients and GPs,
and the consequential reduction in the prescribing of
antibiotics will contribute to global strategies in promot-
ing the better stewardship of antimicrobials.
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